Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
three-drug antiretroviral prophylaxis-University of North Carolina, Chapel Hill-HIV infection
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This refers to a triple-drug antiretroviral therapy (HAART) regimen evaluated by the University of North Carolina at Chapel Hill for the prevention of mother-to-child transmission (PMTCT) of HIV in rural Zambia. The primary regimen evaluated in the study (NCT00495326) consists of zidovudine (ZDV), lamivudine (3TC), and nevirapine (NVP). Alternative combinations include lopinavir/ritonavir as a substitute for nevirapine, and stavudine (d4T) as a substitute for zidovudine in patients with moderate to severe anemia. These drugs work by inhibiting HIV-1 reverse transcriptase (NRTIs and NNRTIs) or HIV-1 protease, thereby suppressing maternal viral load and reducing the risk of vertical transmission during pregnancy and delivery.
- Other names
- Routine three-drug antiretroviral prophylaxisHAARTHighly Active Antiretroviral TherapyTriple-drug antiretroviral therapy
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasegp41 (Human immunodeficiency virus type 1 glycoprotein 41)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on three-drug antiretroviral prophylaxis-University of North Carolina, Chapel Hill-HIV infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on three-drug antiretroviral prophylaxis-University of North Carolina, Chapel Hill-HIV infection.